ダウンロード数: 137
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
circj.CJ-19-0515.pdf | 5.95 MB | Adobe PDF | 見る/開く |
タイトル: | Cancer-Associated Venous Thromboembolism in the Real World --From the COMMAND VTE Registry-- |
著者: | Sakamoto, Jiro Yamashita, Yugo Morimoto, Takeshi Amano, Hidewo Takase, Toru Hiramori, Seiichi Kim, Kitae Oi, Maki Akao, Masaharu Kobayashi, Yohei Toyofuku, Mamoru Izumi, Toshiaki Tada, Tomohisa Chen, Po-Min Murata, Koichiro Tsuyuki, Yoshiaki Saga, Syunsuke Nishimoto, Yuji Sasa, Tomoki Kinoshita, Minako Togi, Kiyonori Mabuchi, Hiroshi Takabayashi, Kensuke Yoshikawa, Yusuke Shiomi, Hiroki Kato, Takao https://orcid.org/0000-0001-8213-7999 (unconfirmed) Makiyama, Takeru https://orcid.org/0000-0002-9471-5335 (unconfirmed) Ono, Koh Tamura, Toshihiro Nakagawa, Yoshihisa Kimura, Takeshi |
著者名の別形: | 山下, 侑吾 塩見, 紘樹 加藤, 貴雄 牧山, 武 尾野, 亘 木村, 剛 |
キーワード: | Bleeding Cancer Mortality Recurrence Venous thromboembolism |
発行日: | 25-Oct-2019 |
出版者: | Japanese Circulation Society |
誌名: | Circulation Journal |
巻: | 83 |
号: | 11 |
開始ページ: | 2271 |
終了ページ: | 2281 |
抄録: | Background:There is a paucity of data on the management and prognosis of cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal management strategies. Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3, 027 consecutive acute symptomatic VTE patients in Japan between 2010 and 2014. We divided the entire cohort into 3 groups: active cancer (n=695, 23%), history of cancer (n=243, 8%), and no history of cancer (n=2089, 69%). The rate of anticoagulation discontinuation was higher in patients with active cancer (43.5%, 27.0%, and 27.0%, respectively, at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding, and all-cause death were higher in patients with active cancer (recurrent VTE: 17.7%, 10.2%, and 8.6%, P<0.001; major bleeding: 26.6%, 8.8%, and 9.3%, P<0.001; all-cause death: 73.1%, 28.6%, 14.6%, P<0.001). Among the 4 groups classified according to active cancer status, the cumulative 1-year incidence of recurrent VTE was higher in the metastasis group (terminal stage group: 6.4%, metastasis group: 22.1%, under chemotherapy group: 10.8%, and other group: 5.8%, P<0.001). Conclusions:In a current real-world VTE registry, patients with active cancer had higher risk for VTE recurrence, bleeding, and death, with variations according to cancer status, than patients without active cancer. Anticoagulation therapy was frequently discontinued prematurely in patients with active cancer in discordance with current guideline recommendations. |
著作権等: | © 2019 THE JAPANESE CIRCULATION SOCIETY Publisher permitted to deposit this paper on this repository. |
URI: | http://hdl.handle.net/2433/244812 |
DOI(出版社版): | 10.1253/circj.CJ-19-0515 |
PubMed ID: | 31548438 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。